Evolent Health [EVH] vs GoodRx Holdings [GDRX] Detailed Stock Comparison
Evolent Health
NYSE
Loading...
GoodRx Holdings
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Evolent Health wins in 9 metrics, GoodRx Holdings wins in 10 metrics, with 0 ties. GoodRx Holdings appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Evolent Health | GoodRx Holdings | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -10.16 | 50.33 | Evolent Health |
| Price-to-Book Ratio | 1.06 | 2.46 | Evolent Health |
| Debt-to-Equity Ratio | 75.85 | 85.15 | Evolent Health |
| PEG Ratio | -0.02 | 0.50 | Evolent Health |
| EV/EBITDA | 26.10 | 13.67 | GoodRx Holdings |
| Profit Margin (TTM) | -5.94% | 4.33% | GoodRx Holdings |
| Operating Margin (TTM) | 0.64% | 13.20% | GoodRx Holdings |
| EBITDA Margin (TTM) | 0.64% | 13.20% | GoodRx Holdings |
| Return on Equity | -11.04% | 5.27% | GoodRx Holdings |
| Return on Assets (TTM) | -0.21% | 5.08% | GoodRx Holdings |
| Free Cash Flow (TTM) | $-6.13M | $113.55M | GoodRx Holdings |
| 1-Year Return | -69.51% | -33.62% | GoodRx Holdings |
| Price-to-Sales Ratio (TTM) | 0.43 | 1.97 | Evolent Health |
| Enterprise Value | $1.89B | $1.84B | Evolent Health |
| EV/Revenue Ratio | 0.86 | 2.30 | Evolent Health |
| Gross Profit Margin (TTM) | 22.59% | 93.43% | GoodRx Holdings |
| Revenue per Share (TTM) | $19 | $2 | Evolent Health |
| Earnings per Share (Diluted) | $-1.60 | $0.09 | GoodRx Holdings |
| Beta (Stock Volatility) | 0.66 | 1.23 | Evolent Health |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Evolent Health vs GoodRx Holdings Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Evolent Health | 0.24% | -5.93% | -14.68% | -29.12% | -12.23% | -28.20% |
| GoodRx Holdings | 1.10% | 6.76% | 11.17% | -3.38% | 14.21% | 0.44% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Evolent Health | -69.51% | -73.47% | -27.18% | -49.82% | -56.26% | -56.26% |
| GoodRx Holdings | -33.62% | -3.58% | -91.36% | -91.20% | -91.20% | -91.20% |
News Based Sentiment: Evolent Health vs GoodRx Holdings
Evolent Health
News based Sentiment: NEGATIVE
October was a significantly negative month for Evolent Health, with a substantial earnings miss, revenue decline, and a sharp drop in share price. While some analysts maintain a positive outlook, the overall narrative points to increased risk and uncertainty for investors, making it a crucial period for the company to demonstrate a turnaround.
GoodRx Holdings
News based Sentiment: MIXED
October was a pivotal month for GoodRx, marked by a significant stock surge due to potential partnerships, but tempered by earnings misses, analyst caution, and insider selling. The company's future hinges on successfully navigating these competing forces and capitalizing on new opportunities while mitigating existing risks.
Performance & Financial Health Analysis: Evolent Health vs GoodRx Holdings
| Metric | EVH | GDRX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.06B | $1.57B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 3,100,400 | 5,292,330 |
| 90 Day Avg. Volume | 3,139,787 | 3,495,567 |
| Last Close | $8.25 | $4.58 |
| 52 Week Range | $7.06 - $27.42 | $3.31 - $7.20 |
| % from 52W High | -69.91% | -36.43% |
| All-Time High | $39.78 (Sep 12, 2022) | $64.22 (Sep 28, 2020) |
| % from All-Time High | -79.26% | -92.87% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.31% | 0.01% |
| Quarterly Earnings Growth | N/A | 0.92% |
| Financial Health | ||
| Profit Margin (TTM) | -0.06% | 0.04% |
| Operating Margin (TTM) | 0.01% | 0.13% |
| Return on Equity (TTM) | -0.11% | 0.05% |
| Debt to Equity (MRQ) | 75.85 | 85.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.73 | $1.84 |
| Cash per Share (MRQ) | $1.30 | $0.81 |
| Operating Cash Flow (TTM) | $-33,330,000 | $190.60M |
| Levered Free Cash Flow (TTM) | $-77,390,624 | $124.38M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Evolent Health vs GoodRx Holdings
| Metric | EVH | GDRX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -10.16 | 50.33 |
| Forward P/E | 5.76 | 11.05 |
| PEG Ratio | -0.02 | 0.50 |
| Price to Sales (TTM) | 0.43 | 1.97 |
| Price to Book (MRQ) | 1.06 | 2.46 |
| Market Capitalization | ||
| Market Capitalization | $1.06B | $1.57B |
| Enterprise Value | $1.89B | $1.84B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.86 | 2.30 |
| Enterprise to EBITDA | 26.10 | 13.67 |
| Risk & Other Metrics | ||
| Beta | 0.66 | 1.23 |
| Book Value per Share (MRQ) | $7.73 | $1.84 |
Financial Statements Comparison: Evolent Health vs GoodRx Holdings
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | EVH | GDRX |
|---|---|---|
| Revenue/Sales | $483.65M | $202.97M |
| Cost of Goods Sold | $381.18M | $13.36M |
| Gross Profit | $102.47M | $189.61M |
| Research & Development | N/A | $31.14M |
| Operating Income (EBIT) | $4,000 | $23.38M |
| EBITDA | $25.27M | $48.22M |
| Pre-Tax Income | $-63.15M | $16.67M |
| Income Tax | $1.47M | $5.62M |
| Net Income (Profit) | $-64.62M | $11.05M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | EVH | GDRX |
|---|---|---|
| Cash & Equivalents | $246.55M | $300.98M |
| Total Current Assets | $727.93M | $540.21M |
| Total Current Liabilities | $739.10M | $103.38M |
| Long-Term Debt | $663.12M | $530.63M |
| Total Shareholders Equity | $935.52M | $654.35M |
| Retained Earnings | $-845.44M | $-1.43B |
| Property, Plant & Equipment | $5.73M | $34.41M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | EVH | GDRX |
|---|---|---|
| Operating Cash Flow | $-23.39M | $37.57M |
| Capital Expenditures | N/A | $-142,000 |
| Free Cash Flow | $-4.03M | $-12.46M |
| Debt Repayment | $-62.50M | $-1.25M |
| Common Stock Repurchase | N/A | $-99.90M |
Short Interest & Institutional Ownership Analysis
| Metric | EVH | GDRX |
|---|---|---|
| Shares Short | 23.10M | 5.59M |
| Short Ratio | 7.22 | 0.97 |
| Short % of Float | 0.20% | 0.06% |
| Average Daily Volume (10 Day) | 3,100,400 | 5,292,330 |
| Average Daily Volume (90 Day) | 3,139,787 | 3,495,567 |
| Shares Outstanding | 115.04M | 382.82M |
| Float Shares | 91.32M | 86.43M |
| % Held by Insiders | 0.02% | 0.13% |
| % Held by Institutions | 1.09% | 0.62% |
Dividend Analysis & Yield Comparison: Evolent Health vs GoodRx Holdings
| Metric | EVH | GDRX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |